Background: Scirrhous gastric cancer (SGC) is highly invasive and metastatic because of its interactions with stromal cells, such as fibroblasts and macrophages, and extracellular matrix, leading to a higher incidence of peritoneal metastasis (PM) than other gastric cancers (GCs). Taxane-based intraperitoneal chemotherapy (IPC) is a promising therapy for PM. We retrospectively analyzed outcomes of multidisciplinary therapies that included IPC for SGC.
Patients and therapy: Of 1,679 GC patients treated between 1990 and 2012, we analyzed 119 patients who underwent multidisciplinary therapy for SGC. Patients without PM received gastrectomy with lymphadenectomy and resection of involved adjacent organs followed by intraoperative IPC using cisplatin. Patients with PM received chemotherapy using fluorouracil, with or without methotrexate plus IPC using cisplatin before 2000, and S-1 plus IPC using paclitaxel or docetaxel since 2000.
Results: Of the 119 patients, 73 (61%) had PM and 63 (53%) had positive peritoneal lavage cytology. Of the 89 gastrectomy patients, 30 (34%) had macroscopic residual tumors (R2). Of the patients treated since 2000, 66 (100%) received S-1 plus taxanes and 44 patients (67%) received taxane-based IPC. Median survival time was significantly longer in the post-2000 group (22.8 months) than in the pre-2000 group (9.5 months). In univariate analysis, lavage cytology, PM, taxane-based IPC, gastrectomy, and R2 resection were significant prognostic factors. However, only R2 resection was an independent prognostic factor in multivariate analysis (hazard ratio: 5.53, 95% CI: 2.05-14.93).
Conclusion: As use of taxane-based IPC is not an independent prognostic factor, new multidisciplinary therapies are necessary to avoid R2 resections.
Keywords: intraperitoneal chemotherapy; peritoneal metastasis; taxanes.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer.Chemotherapy. 2005 Mar;51(1):15-20. doi: 10.1159/000084018. Epub 2005 Feb 17. Chemotherapy. 2005. PMID: 15722628
Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma.Ann Surg. 2009 Aug;250(2):242-6. doi: 10.1097/SLA.0b013e3181b0c80e. Ann Surg. 2009. PMID: 19638909 Clinical Trial.
Management protocol for scirrhous gastric cancer.In Vivo. 2004 Sep-Oct;18(5):577-80. In Vivo. 2004. PMID: 15523896 Clinical Trial.
[An extended operation for scirrhous gastric cancer--its significance and procedure].Gan To Kagaku Ryoho. 1994 Oct;21(14):2392-7. Gan To Kagaku Ryoho. 1994. PMID: 7944482 Review. Japanese.
Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes.World J Gastrointest Oncol. 2015 Nov 15;7(11):285-91. doi: 10.4251/wjgo.v7.i11.285. World J Gastrointest Oncol. 2015. PMID: 26600928 Free PMC article. Review.
- Kanter MA, Isaacson NH, Knoll AM, Nochomovitz LE. The diagnostic challenge of metastatic linitis plastic. Two cases and a consideration of the problem. Am Surg. 1986;52(9):510–513. - PubMed
- Park MS, Ha HK, Choi BS, et al. Scirrhous gastric carcinoma: endoscopy versus upper gastrointestinal radiography. Radiology. 2004;231(2):421–426. - PubMed
- Furukawa H, Hiratsuka M, Iwanaga T, et al. Extended surgery – left upper abdominal exenteration plus Appleby’s method – for type 4 gastric carcinoma. Ann Surg Oncol. 1997;4(3):209–214. - PubMed
- Suga S, Iwase H, Shimada M, et al. Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Intern Med. 1996;35(12):930–936. - PubMed